Frontotemporal dementia—A brief review

Frontotemporal dementia (FTD) is the second most common type of presenile dementia and the forth most common type of senile dementia, but probably the most costly due to its florid symptom characteristics. Clinically, it often presents with changes of personality, restlessness, disinhibition, and impulsiveness and the clinical features can be complicated by neurological signs, such as motor neuron signs, parkinsonism, and gait disturbances. Syndromatically, FTD can be subdivided into a group with predominating behavioural disturbances (frontal variant) and another with predominating language deterioration (temporal variant). Based on the underlying pathological changes, FTD is nosologically divided into disorders such as Pick's disease, frontotemporal lobar degeneration, corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17). The cause in sporadic FTD is most often unknown, but in FTDP-17, one of the hereditary FTDs, there is a causative mutation in the tau gene. The frequency of tau-gene mutations is low in sporadic FTD and present in about 10-40% of hereditary FTD. Other types of hereditary FTD have been described, such as FTD caused by mutations in chromosome 3, chromosome 9, and a FTD syndrome can also be caused by mutations in the presenilin-1 gene. Since there is no curative, treatment of prevailing symptoms is the given alternative. Serotonergic acting drugs have been shown to alleviate behavioural symptoms.

[1]  J. Morris,et al.  Apolipoprotein E genotype does not affect the age of onset of dementia in families with defined tau mutations , 1999, Neuroscience Letters.

[2]  A. Dahlström,et al.  Alzheimer's disease cerebrospinal fluid antibodies display selectivity for microglia , 1994, Molecular Neurobiology.

[3]  K. Blennow,et al.  The Cerebrospinal Fluid Levels of Tau, Growth-Associated Protein-43 and Soluble Amyloid Precursor Protein Correlate in Alzheimer’s Disease, Reflecting a Common Pathophysiological Process , 2001, Dementia and Geriatric Cognitive Disorders.

[4]  J. Hardy,et al.  A Presenilin 1 Mutation Associated with Familial Frontotemporal Dementia Inhibits γ-Secretase Cleavage of APP and Notch , 2002, Neurobiology of Disease.

[5]  J. Trojanowski,et al.  Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia , 2001, Annals of neurology.

[6]  R. Brandt,et al.  Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain , 1995, The Journal of cell biology.

[7]  J. Trojanowski,et al.  Attenuated Neurodegenerative Disease Phenotype in Tau Transgenic Mouse Lacking Neurofilaments , 2001, The Journal of Neuroscience.

[8]  A D Roses,et al.  Apolipoprotein E alleles as risk factors in Alzheimer's disease. , 1996, Annual review of medicine.

[9]  T. Poulos,et al.  Aspartate residue 7 in amyloid β-protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis , 1997, Nature Medicine.

[10]  T D Bird,et al.  Familial frontotemporal dementia with ubiquitin-positive, tau-negative inclusions , 2000, Neurology.

[11]  M. Gearing,et al.  Apolipoprotein E genotype in diverse neurodegenerative disorders , 1995, Annals of neurology.

[12]  Linda Clare,et al.  The ‘Talking About Memory Coffee Group’: A new model of support for people with early-stage dementia and their families , 2005 .

[13]  J. Haines,et al.  Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. , 2000, JAMA.

[14]  M. Kamboh,et al.  Apolipoprotein E polymorphism and susceptibility to Alzheimer's disease. , 1995, Human biology.

[15]  F. Lhermitte,et al.  Human autonomy and the frontal lobes. Part II: Patient behavior in complex and social situations: The “environmental dependency syndrome” , 1986, Annals of neurology.

[16]  D. Campion,et al.  Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation , 2000, Neurology.

[17]  P. Scheltens,et al.  Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations. , 2003, Archives of neurology.

[18]  J. T. Coull,et al.  Theα2 antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type , 1996, Psychopharmacology.

[19]  K. Blennow,et al.  Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD , 2000, Neurology.

[20]  J. Breitner The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. , 1996, Annual review of medicine.

[21]  A. Brun,et al.  Molecular Genetic Characterisation of Frontotemporal Dementia on Chromosome 3 , 1999, Dementia and Geriatric Cognitive Disorders.

[22]  M. Trabucchi,et al.  Alzheimer disease and frontotemporal dementia. , 1997, Archives of neurology.

[23]  R. Petersen,et al.  Familial Frontotemporal Dementia Associated with a Novel Presenilin-1 Mutation , 2002, Dementia and Geriatric Cognitive Disorders.

[24]  D. Neary,et al.  Apolipoprotein E allelic frequencies in patients with lobar atrophy , 1995, Neuroscience Letters.

[25]  P. de Knijff,et al.  Apolipoprotein E gene and sporadic frontal lobe dementia , 1997, Neurology.

[26]  D. Geschwind,et al.  The apolipoprotein E ε4 allele is not a significant risk factor for frontotemporal dementia , 1998 .

[27]  Nick C Fox,et al.  Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration , 2003, International journal of geriatric psychiatry.

[28]  L. Farrer,et al.  Allele ϵ4 of Apolipoprotein E Shows a Dose Effect on Age at Onset of Pick Disease , 1995, Experimental Neurology.

[29]  L. Gustafson,et al.  Clinical picture of frontal lobe degeneration of non-Alzheimer type. , 1993, Dementia.

[30]  J. Bauer,et al.  The participation of interleukin-6, a stress-inducible cytokine, in the pathogenesis of Alzheimer's disease , 1996, Behavioural Brain Research.

[31]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[32]  J. Risberg,et al.  Multichannel EEG frequency analysis and somatosensory-evoked potentials in patients with different types of organic dementia. , 1993, Dementia.

[33]  B L Miller,et al.  Alzheimer disease and frontotemporal dementias. Behavioral distinctions. , 1996, Archives of neurology.

[34]  J. Constantinidis,et al.  Pick’s Disease , 1974 .

[35]  F. Pasquier,et al.  Personality traits and frontal lobe dementia , 1995 .

[36]  P. Mecocci,et al.  Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease? , 1998, Alzheimer disease and associated disorders.

[37]  M N Rossor,et al.  Semantic dementia with ubiquitin-positive tau-negative inclusion bodies. , 2000, Brain : a journal of neurology.

[38]  M. Abrahamson,et al.  Apolipoprotein-E genotyping in Alzheimer's disease and frontotemporal dementia. , 1997, Dementia and geriatric cognitive disorders.

[39]  R. Mayer,et al.  Ballooned neurons in several neurodegenerative diseases and stroke contain αB crystallin , 1992 .

[40]  K. Blennow,et al.  Both total and phosphorylated tau are increased in Alzheimer's disease , 2001, Journal of neurology, neurosurgery, and psychiatry.

[41]  D. Ingvar,et al.  EEG and cognitive impairment in presenile dementia , 1979, Acta neurologica Scandinavica.

[42]  C. V. van Duijn,et al.  Medical and environmental risk factors for sporadic frontotemporal dementia: a retrospective case–control study , 2003, Journal of neurology, neurosurgery, and psychiatry.

[43]  B Miller,et al.  Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. , 2001, Archives of neurology.

[44]  Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. , 1997, The Journal of clinical psychiatry.

[45]  G. Pasinetti Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: The role of the complement system , 1996, Neurobiology of Aging.

[46]  C. Schneider Über Picksche Krankheit. pp. 230–252 , 1927 .

[47]  R. Petersen,et al.  Frequency of tau mutations in three series of non‐Alzheimer's degenerative dementia , 1999, Annals of neurology.

[48]  K. Boone,et al.  A study of the Lund‐Manchester research criteria for frontotemporal dementia , 1997, Neurology.

[49]  D. Neary,et al.  Dementia of frontal lobe type. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[50]  B. Miller,et al.  Frontotemporal dementia: Neuropil spheroids and presynaptic terminal degeneration , 1998, Annals of neurology.

[51]  M. Sjögren,et al.  Pathophysiological aspects of frontotemporal dementia—emphasis on cytoskeleton proteins and autoimmunity , 2001, Mechanisms of Ageing and Development.

[52]  J. Risberg,et al.  Regional cerebral blood flow measurements in the clinical evaluation of demented patients. , 1997, Dementia and geriatric cognitive disorders.

[53]  F. Pasquier,et al.  Natural History of Frontotemporal Dementia: Comparison with Alzheimer’s Disease , 2004, Dementia and Geriatric Cognitive Disorders.

[54]  M. Mendez,et al.  Emergent neuroleptic hypersensitivity as a herald of presenile dementia. , 2001, The Journal of neuropsychiatry and clinical neurosciences.

[55]  C. Duijn,et al.  High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. , 1999, American journal of human genetics.

[56]  Mark A. Levenstien,et al.  Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. , 2001, Molecular genetics and metabolism.

[57]  B. Miller,et al.  Aggressive, socially disruptive and antisocial behaviour associated with fronto-temporal dementia , 1997, British Journal of Psychiatry.

[58]  K. Blennow,et al.  Prevalence and Incidence of Clinically Diagnosed Memory Impairments in a Geographically Defined General Population in Sweden , 1999, Neuroepidemiology.

[59]  G. Livingston,et al.  Islington study of dementia subtypes in the community. , 2002, The British journal of psychiatry : the journal of mental science.

[60]  J. Garcìa,et al.  Ballooned neurons in select neurodegenerative diseases contain phosphorylated neurofilament epitopes , 2004, Acta Neuropathologica.

[61]  B L Miller,et al.  Dietary changes, compulsions and sexual behavior in frontotemporal degeneration. , 1995, Dementia.

[62]  G. Leuba,et al.  Search for a Mutation in the tau Gene in a Swiss Family with Frontotemporal Dementia , 2000, Experimental Neurology.

[63]  Florence Pasquier,et al.  The Clinical Picture of Frontotemporal Dementia: Diagnosis and Follow-Up , 1999, Dementia and Geriatric Cognitive Disorders.

[64]  D. Knopman,et al.  Overview of dementia lacking distinctive histology: pathological designation of a progressive dementia. , 1993, Dementia.

[65]  A. Bava,et al.  Frontotemporal Dementia: Paroxetine as a Possible Treatment of Behavior Symptoms , 2002, European Neurology.

[66]  D. Neary,et al.  Fronto-temporal Dementia: Nosology, Neuropsychology, and Neuropathology , 1996, Brain and Cognition.

[67]  R. Tissot,et al.  Role of glutamate and zinc in the hippocampal lesions of Pick's disease. , 1981, Advances in biochemical psychopharmacology.

[68]  C. Masters,et al.  Alternative transcripts of presenilin‐1 associated with frontotemporal dementia , 2002, Neuroreport.

[69]  D. Neary,et al.  Progressive language dysfunction and lobar atrophy. , 1993, Dementia.

[70]  K. Blennow,et al.  Clinic-Based Cases with Frontotemporal Dementia Show Increased Cerebrospinal Fluid Tau and High Apolipoprotein E ε4 Frequency, but No Tau Gene Mutations , 2001, Experimental Neurology.

[71]  J. Hodges,et al.  Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. , 1992 .

[72]  K. Blennow,et al.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.

[73]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[74]  G. Schellenberg,et al.  Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer dementia. , 2001, Archives of neurology.

[75]  Philip Scheltens,et al.  Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. , 2003, Brain : a journal of neurology.

[76]  T. Sjogren,et al.  Morbus Alzheimer and morbus Pick; a genetic, clinical and patho-anatomical study. , 1952, Acta psychiatrica et neurologica Scandinavica. Supplementum.

[77]  M. Spillantini,et al.  Tau gene mutations: dissecting the pathogenesis of FTDP-17. , 2002, Trends in molecular medicine.

[78]  K. Blennow,et al.  The apolipoprotein E ϵ4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease , 1997, Neuroscience Letters.

[79]  Katharina Buerger,et al.  Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. , 2004, Archives of general psychiatry.

[80]  M. Hutton,et al.  The molecular genetics of the tauopathies , 2000, Experimental Gerontology.

[81]  K. Blennow,et al.  Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[82]  D. Ingvar,et al.  EEG IN PRESENILE DEMENTIA RELATED TO CEREBRAL BLOOD FLOW AND AUTOPSY FINDINGS , 1977, Acta neurologica Scandinavica.

[83]  P Julin,et al.  Clinical diagnosis of frontal lobe dementia and Alzheimer's disease: relation to cerebral perfusion, brain atrophy and electroencephalography. , 1995, Dementia.

[84]  J. Cummings,et al.  Kluver‐Bucy Syndrome in Pick disease , 1981, Neurology.